RxDoctor Payments DataLook up a doctor →

James McKay

Rheumatology · Tulsa, OKNPI 1205840436

Payments from drug & device makers

$944,900in general payments, 2019–2025

Across 393 payments — averaging $2404.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$585K
  • Gilead$211K
  • Amgen$85K
  • Astrazeneca UK Limited$41K
  • GSK$19K
  • AbbVie$716
  • plus $3K from 16 others

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC20$585,276
Gilead39$211,172
Amgen56$85,034
Astrazeneca UK Limited1$40,614
GSK31$19,090
AbbVie48$716
Mallinckrodt Hospital Products Inc.21$440
Lilly USA, LLC22$380
Genentech USA, Inc.27$370
UCB, Inc.21$309
Johnson & Johnson29$289
E.r. Squibb & Sons, L.L.C.18$284
Mallinckrodt Enterprises LLC15$263
Pfizer18$182
Radius Health, Inc.9$137
Regeneron Healthcare Solutions, Inc.4$123
Bristol Myers Squibb5$89
Aurinia Pharma U.S., Inc.4$76
Novartis2$22
Medtronic1$18
AstraZeneca1$12
Actelion Pharmaceuticals US, Inc.1$5

How this compares

$944,900 in reported general payments places this provider in the 90th percentile of 67 rheumatology providers in Oklahoma.

See all rheumatology providers in Oklahoma →

Other rheumatology in Tulsa

See the full list for Oklahoma →

Where these figures come from

Is this you, or does something look wrong? →